PDS Biotech gets Nasdaq notice after shares trade below $1 bid-price minimum
PDSB•Cure period and possible remedies
Nasdaq set a 180-day cure period through Jan. 26, 2027; compliance requires a $1+ closing bid for at least 10 consecutive sessions.
Failure to cure by the deadline could trigger delisting; the company may consider a reverse stock split to address the deficiency.
Nasdaq notice over bid-price rule
PDS Biotechnology received a Nasdaq notice for failing the $1 minimum bid price rule, with shares below $1 for 30 straight sessions.
The stock remains listed on the Nasdaq Capital Market under PDSB while the company works to regain compliance.
